IMDX (Insight Molecular Diagnostics) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.42
GF Value $1.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Insight Molecular Diagnostics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

IMDX vs BDSX, XGN, FONR: Margin of Safety % (DCF FCF Based) Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insight Molecular Diagnostics Margin of Safety % (DCF FCF Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Margin of Safety % (DCF FCF Based) falls into.


IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.42 is trading 330.2% above its estimated GF Value™ of $1.26. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $1.26 vs. price of $5.42 (330.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.42
Price
$1.26
GF Value